top of page

Burjeel Holdings and BridgeBio Pharma Usher in a New Era of Rare Disease Research with Project 'NADE

Burjeel Holdings, a renowned healthcare provider in the MENA region, and BridgeBio Pharma, Inc., a company with a strong focus on genetic diseases and cancers, have recently announced a pioneering project that aims to transform the landscape of rare disease diagnosis and treatment in the UAE and beyond. This trailblazing initiative, known as Project 'NADER' (Needs Assessment and Therapeutics Development for Rare Diseases), signifies a significant collaboration between the two entities, with the potential to change countless lives.

Project 'NADER': A Beacon of Hope

Project 'NADER' represents a beacon of hope for individuals suffering from rare diseases. These diseases, often genetic, pose a significant threat to the small percentage of the population they affect. Despite their rarity, the impact of these diseases is significant, often leading to life-threatening or chronically debilitating conditions that persist throughout an individual's life.

The intention of the project is to revolutionize the early diagnosis and treatment of these rare diseases, potentially improving patient outcomes. The collaboration aims to identify patients with several rare diseases, such as achondroplasia, hypochondroplasia, autosomal dominant hypocalcemia type 1, limb girdle muscular dystrophy type 2i, and others.

The goal is to intervene as early as possible to avoid disease progression, and to provide access to advanced therapies or clinical trial options for patients who have already been diagnosed but do not currently have access to such opportunities.

An Innovative Approach to Diagnosis

The first phase of project 'NADER' will leverage innovative risk assessment algorithms to identify patients at risk for specific rare diseases. These algorithms will be deployed through the healthcare provider's secure internal data.

Future phases of the project plan to analyze vast amounts of data to identify patterns and markers associated with the diseases and generate personalized risk scores for patients. The project also aims to run awareness campaigns and education activities about such rare diseases, to further support the mapping activity and encourage local collaborations from other healthcare providers.

A Mutually Beneficial Partnership

The collaboration between Burjeel Holdings and BridgeBio Pharma brings together the strengths of both entities. Burjeel Holdings' expertise in healthcare delivery and outreach complements BridgeBio's extensive experience in delivering breakthrough therapies for rare diseases.

John Sunil, CEO of Burjeel Holdings, believes that Project 'NADER' is a significant milestone in their commitment to delivering the best possible care to their patients. He said, "By combining our strengths, we seek to address the challenges faced in the identification of rare diseases, which often go undiagnosed until symptoms become severe. The project will enable early interventions, whether in the form of established treatments or novel therapies."

Neil Kumar, Ph.D., BridgeBio founder and CEO, echoed these sentiments, expressing his hope that the collaboration could expand their efforts in the MENA region and provide more patients with access to novel treatments, clinical trials, and capabilities.

The Future of Rare Disease Treatment in the MENA Region

As the partnership unfolds, both Burjeel Holdings and BridgeBio anticipate significant progress in the field of rare diseases in the region. They also expect to provide patients in the region with increased access to BridgeBio's advanced pharmacologic and gene therapies that are currently in development.

Burjeel Holdings has plans to deploy the project across its widespread hospitals and medical centers across the UAE, with plans to expand the project through its growing healthcare infrastructure in the region.

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is one of the leading private healthcare services providers in the MENA region. With a network of 62 assets, including 16 hospitals and 24 medical centers, the group provides the highest standard of patient care in the region.

About BridgeBio Pharma, Inc.

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.

In conclusion, the collaboration between Burjeel Holdings and BridgeBio Pharma promises to be a game-changer in the field of rare diseases. Project 'NADER' represents a significant step towards better diagnosis, treatment, and understanding of these diseases, bringing hope to countless patients in the UAE and beyond. With this innovative approach, the future of rare disease treatment in the MENA region looks promising.


Recent Posts

See All

Biogen's Acquisition of Reata Pharmaceuticals

Introduction In a significant development for the medical community, Biogen Inc. (Nasdaq: BIIB) has announced its definitive agreement to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA). This strat


bottom of page